Parkinson’s disease 2X more likely if low Vitamin D – meta-analysis May 2014

Vitamin D status and Parkinson’s disease: a systematic review and meta-analysis

Neurological Sciences, May 2014
Zheng Lv, Huiping Qi, Le Wang, Xiaoxue Fan, Fei Han, Hong Wang, Sheng Bi 13224510036 at 163.com
1. Department of Rehabilitation, the First Affiliated Hospital, Harbin Medical University, Harbin, 150001, China
2. Department of Neurology, the Fourth Affiliated Hospital, Harbin Medical University, Harbin, 150001, China
3. Department of Neurology, the First Affiliated Hospital, Harbin Medical University, Harbin, 150001, China

To estimate the associations between vitamin D status and Parkinson’s disease (PD). We searched electronic databases of the human literature in PubMed, EMBASE and the Cochrane Library up to February, 2014 using the following keywords: ‘vitamin D’ or ‘25(OH)D’ and ‘status’ or ‘deficiency’ or ‘insufficiency’ and ‘Parkinson’s disease’. A systematic review and meta-analysis were conducted on observational studies that reported the association between blood vitamin D levels and PD. Seven studies met the inclusion criteria. 1,008 patients and 4,536 controls were included.
Results of our meta-analysis show that PD patients had lower mean levels of 25-hydroxyvitamin D [25(OH)D] than healthy controls [weighted mean difference (MD), −16.9, 95 % confidence interval (CI)], −33.5 to −0.2).
Patients with vitamin D insufficiency [25(OH)D level <75 nmol/l] had an increased risk of PD (OR 1.5, 95 % CI 1.1–2.0).
Patients with vitamin D deficiency [25(OH)D level <50 nmol/l] experienced a twofold increased risk of PD (OR 2.2, 95 % CI 1.5–3.4). Low vitamin D levels are associated with an increased risk of PD.

References

1. Dick FD, De Palma G, Ahmadi A, Scott NW, Prescott GJ, Bennett J, Semple S, Dick S, Counsell C, Mozzoni P, Haites N, Wettinger SB, Mutti A, Otelea M, Seaton A, Söderkvist P, Felice A, Geoparkinson study group (2007) Environmental risk factors for Parkinson’s disease and parkinsonism: the Geoparkinson study. Occup Environ Med 64(10):666–672 CrossRef
2. Hancock DB, Martin ER, Mayhew GM, Stajich JM, Jewett R, Stacy MA, Scott BL, Vance JM, Scott WK (2008) Pesticide exposure and risk of Parkinson’s disease: a family-based case–control study. BMC Neurol 8(3):6 CrossRef
3. Henchcliffe C, Beal MF (2008) Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol 4(11):600–609 CrossRef
4. DeLuca GC, Kimball SM, Kolasinski J, Ramagopalan SV, Ebers GC (2013) Review: the role of vitamin D in nervous system health and disease. Neuropathol Appl Neurobiol 39(5):458–484 CrossRef
5. Zittermann A, Schleithoff SS, Koerfer R (2006) Vitamin D insufficiency in congestive heart failure: why and what to do about it? Heart Fail Rev 11(1):25–33 CrossRef
6. Chaudhuri JR, Mridula KR, Alladi S, Anamika A, Umamahesh M, Balaraju B, Swath A, Bandaru VS (2014) Serum 25-hydroxyvitamin D deficiency in ischemic stroke and subtypes in Indian patients. J Stroke 16(1):44–50 CrossRef
7. Brøndum-Jacobsen P, Nordestgaard BG, Schnohr P, Benn M (2013) 25-hydroxyvitamin D and symptomatic ischemic stroke: an original study and meta-analysis. Ann Neurol 73(1):38–47 CrossRef
8. Martinelli V, Dalla Costa G, Colombo B, Dalla Libera D, Rubinacci A, Filippi M, Furlan R, Comi G (2014) Vitamin D levels and risk of multiple sclerosis in patients with clinically isolated syndromes. Mult Scler 20(2):147–155 CrossRef
9. Guzmán-Fulgencio M, García-Álvarez M, Berenguer J, Jiménez-Sousa MÁ, Cosín J, Pineda-Tenor D, Carrero A, Aldámiz T, Alvarez E, López JC, Resino S (2014) Vitamin D deficiency is associated with severity of liver disease in HIV/HCV coinfected patients. J Infect 68(2):176–184 CrossRef
10. Camargo CA Jr, Manson JE (2014) Vitamin D supplementation and risk of infectious disease: no easy answers. Am J Clin Nutr 99(1):3–4 CrossRef
11. Gorham ED, Garland CF, Garland FC, Grant WB, Mohr SB, Lipkin M, Newmark HL, Giovannucci E, Wei M, Holick MF (2007) Optimal vitamin D status for colorectal cancer prevention: a quantitative meta-analysis. Am J Prev Med 32(3):210–216 CrossRef
12. Evatt ML (2010) Beyond vitamin status: is there a role for vitamin D in Parkinson disease? Arch Neurol 67(7):795–797 CrossRef
13. Newmark HL, Newmark J (2007) Vitamin D and Parkinson’s disease––a hypothesis. Mov Disord 22(4):461–468 CrossRef
14. Evatt ML, DeLong MR, Kumari M, Auinger P, McDermott MP, Tangpricha V, Parkinson Study Group DATATOP Investigators (2011) High prevalence of hypovitaminosis D status in patients with early Parkinson disease. Arch Neurol 68(3):314–319 CrossRef
15. Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ (2005) Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat 29(1):21–30 CrossRef
16. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta- analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283(15):2008–2012 CrossRef
17. Duckitt K, Harrington D (2005) Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 330(7491):565 CrossRef
18. Holick MF (2007) Vitamin D deficiency. N Engl J Med 357(3):266–281 CrossRef
19. Abou-Raya S, Helmii M, Abou-Raya A (2009) Bone and mineral metabolism in older adults with Parkinson’s disease. Age Ageing 38(6):675–680 CrossRef
20. van den Bos F, Speelman AD, van Nimwegen M, van der Schouw YT, Backx FJ, Bloem BR, Munneke M, Verhaar HJ (2013) Bone mineral density and vitamin D status in Parkinson’s disease patients. J Neurol 260(3):754–760 CrossRef
21. Ding H, Dhima K, Lockhart KC, Locascio JJ, Hoesing AN, Duong K, Trisini-Lipsanopoulos A, Hayes MT, Sohur US, Wills AM, Mollenhauer B, Flaherty AW, Hung AY, Mejia N, Khurana V, Gomperts SN, Selkoe DJ, Schwarzschild MA, Schlossmacher MG, Hyman BT, Sudarsky LR, Growdon JH, Scherzer CR (2013) Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study. Neurology 81(17):1531–1537 CrossRef
22. Evatt ML, Delong MR, Khazai N, Rosen A, Triche S, Tangpricha V (2008) Prevalence of vitamin D insufficiency in patients with Parkinson disease and Alzheimer disease. Arch Neurol 65(10):1348–1352 CrossRef
23. Knekt P, Kilkkinen A, Rissanen H, Marniemi J, Sääksjärvi K, Heliövaara M (2010) Serum vitamin D and the risk of Parkinson disease. Arch Neurol 67(7):808–811 CrossRef
24. Sato Y, Honda Y, Kaji M, Asoh T, Hosokawa K, Kondo I, Satoh K (2002) Amelioration of osteoporosis by menatetrenone in elderly female Parkinson’s disease patients with vitamin D deficiency. Bone 31(1):114–118 CrossRef
25. Sato Y, Honda Y, Iwamoto J, Kanoko T, Satoh K (2005) Abnormal bone and calcium metabolism in immobilized Parkinson’s disease patients. Mov Disord 20(12):1598–1603 CrossRef
26. Egan KM, Signorello LB, Munro HM, Hargreaves MK, Hollis BW, Blot WJ (2008) Vitamin D insufficiency among African–Americans in the southeastern United States: implications for cancer disparities (United States). Cancer Causes Control 19(5):527–535 CrossRef
27. Tsiaras WG, Weinstock MA (2011) Factors influencing vitamin D status. Acta Derm Venereol 91(2):115–124
28. Zhao Y, Sun Y, Ji HF, Shen L (2013) Vitamin D levels in Alzheimer’s and Parkinson’s diseases: a meta-analysis. Nutrition 29(6):828–832 CrossRef
29. Lawson DE, Paul AA, Black AE, Cole TJ, Mandal AR, Davie M (1979) Relative contributions of diet and sunlight to vitamin D state in the elderly. Br Med J 2(6185):303–305 CrossRef
30. Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ (2005) Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat 29(1):21–30 CrossRef
31. Buell JS, Dawson-Hughes B (2008) Vitamin D and neurocognitive dysfunction: preventing “D”ecline? Mol Aspects Med 29(6):415–422 CrossRef
32. Han X, Xue L, Li Y, Chen B, Xie A (2012) Vitamin D receptor gene polymorphism and its association with Parkinson’s disease in Chinese Han population. Neurosci Lett 525(1):29–33 CrossRef

Publisher charges $40 for the PDF

See also Vitamin D Life

Overview Parkinsons and Vitamin D contains the following summary
Parkinson's Disease proven to be TREATED by Vitamin D (Many Meta-analyses of trials)

• Parkinson's disease stabilized with just 1200 IU of vitamin D – RCT May 2013
  First RCT to report results - +anticipate far better results when more vitamin D is used.
     (Belief based on the results with vitamin D on MS and Diabetes)
  Additonal proofs that vitamin D treats or prevents diseases
• 6 clinical trials for PD with vitamin D intervention as of Jan 2016
  A person could wait a few years to get the results of the clinical trials, but
• Based on reading more than 4,000 studies of vitamin D at Vitamin D Life
• A (loading) dose of 20,000 IU of vitamin D daily for the 3 weeks should provide observable benefit
  To avoid a rare reaction to Vitamin D
  take 1,000 IU of vitamin D first, and stop if you you have an allergic reaction withiin 3 days
  When continuing to take vitamin D you should also take cofactors
  There is virtually no need have a vitamin D test in first 2 months
•    Parkinson's category has 82 items

Pages listed in BOTH the categories Parkinson's and Meta-analysis